QPPV.COM KNOWLEDGE ASSESSMENT

Ibrutinib: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Ibrutinib: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A report quotes a pooled US prescribing-information estimate for major haemorrhage across multiple clinical trials. Which interpretation is appropriate?
Question 2 of 10 How should the ELEVATE-RR results be interpreted when discussing acalabrutinib and ibrutinib in previously treated CLL?
Question 3 of 10 A patient has a medically significant adverse event that is clinically moderate in intensity and does not meet a simple laboratory threshold for severe disease. Which principle is most appropriate?
Question 4 of 10 Which approach best evaluates whether a proposed risk-minimisation measure is effective?
Question 5 of 10 Which information is especially valuable when following up a suspected ibrutinib-associated atrial fibrillation case?
Question 6 of 10 In the EU frontline MCL sequence described in the article, a patient experiences an adverse event during a regimen that includes ibrutinib with R-CHOP alternating with R-DHAP or R-DHAOx without ibrutinib. What is the best attribution approach?
Question 7 of 10 Which statement correctly distinguishes public product-information listedness from a company's expectedness assessment?
Question 8 of 10 A serious infection occurs in a patient with a haematological malignancy, prior cytotoxic therapy and current ibrutinib treatment. What is the best causality approach?
Question 9 of 10 A quarterly review finds more spontaneous reports of atrial fibrillation than in the preceding period. What is the most appropriate first interpretation?
Question 10 of 10 An EU SmPC lists a reaction as 'common' and displays a rounded percentage for a pooled dataset. How should a safety assessor use this information?

Select an answer to continue.

QPPV.com